WO2003062376A3 - Molecules for diagnostics and therapeutics - Google Patents
Molecules for diagnostics and therapeutics Download PDFInfo
- Publication number
- WO2003062376A3 WO2003062376A3 PCT/US2003/001096 US0301096W WO03062376A3 WO 2003062376 A3 WO2003062376 A3 WO 2003062376A3 US 0301096 W US0301096 W US 0301096W WO 03062376 A3 WO03062376 A3 WO 03062376A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dithp
- provides
- therapeutics
- diagnostics
- diagnostic assays
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003210518A AU2003210518A1 (en) | 2002-01-16 | 2003-01-13 | Molecules for diagnostics and therapeutics |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34938402P | 2002-01-16 | 2002-01-16 | |
US60/349,384 | 2002-01-16 | ||
US34994602P | 2002-01-17 | 2002-01-17 | |
US34941302P | 2002-01-17 | 2002-01-17 | |
US60/349,946 | 2002-01-17 | ||
US60/349,413 | 2002-01-17 |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10510643 A-371-Of-International | 2003-04-07 | ||
US10/510,643 A-371-Of-International US7906145B2 (en) | 2002-04-09 | 2003-04-07 | Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s) |
US13/014,137 Continuation US10004693B2 (en) | 2002-04-09 | 2011-01-26 | Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s) |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003062376A2 WO2003062376A2 (en) | 2003-07-31 |
WO2003062376A3 true WO2003062376A3 (en) | 2003-12-31 |
Family
ID=27617579
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/001096 WO2003062376A2 (en) | 2002-01-16 | 2003-01-13 | Molecules for diagnostics and therapeutics |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2003210518A1 (en) |
WO (1) | WO2003062376A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9394330B2 (en) | 2012-03-21 | 2016-07-19 | Alios Biopharma, Inc. | Solid forms of a thiophosphoramidate nucleotide prodrug |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004016733A2 (en) | 2002-08-16 | 2004-02-26 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer |
US20090081226A1 (en) * | 2004-12-17 | 2009-03-26 | Inserm (Institut National De La Sante Et De La Recherche Medicle) | Soluble HLA-E Molecules And Their Use For Diagnosing And Treating Pathologies |
FI20050011A (en) * | 2005-01-05 | 2006-07-06 | Jurilab Ltd Oy | Procedure and test package to detect the risk of type 2 diabetes mellitus |
EP1940445B1 (en) | 2005-08-19 | 2011-02-02 | Duke University | Stem cell derived paracrine factor h12 for use in reducing cell death or enhancing tissue repair |
SG188497A1 (en) | 2010-09-22 | 2013-05-31 | Alios Biopharma Inc | Substituted nucleotide analogs |
CA2860234A1 (en) | 2011-12-22 | 2013-06-27 | Alios Biopharma, Inc. | Substituted phosphorothioate nucleotide analogs |
WO2013142157A1 (en) | 2012-03-22 | 2013-09-26 | Alios Biopharma, Inc. | Pharmaceutical combinations comprising a thionucleotide analog |
-
2003
- 2003-01-13 WO PCT/US2003/001096 patent/WO2003062376A2/en not_active Application Discontinuation
- 2003-01-13 AU AU2003210518A patent/AU2003210518A1/en not_active Abandoned
Non-Patent Citations (2)
Title |
---|
MORI K. ET AL.: "MM-1, a novel c-Myc-associating protein that represses transcriptional activity of c-Myc", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, no. 45, 6 November 1998 (1998-11-06), pages 29794 - 29800, XP002971615 * |
SULSTON ET AL.: "Toward a complete human genome sequence", GENOME RESEARCH, vol. 8, November 1998 (1998-11-01), pages 1097 - 1108, XP002181292 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9394330B2 (en) | 2012-03-21 | 2016-07-19 | Alios Biopharma, Inc. | Solid forms of a thiophosphoramidate nucleotide prodrug |
Also Published As
Publication number | Publication date |
---|---|
WO2003062376A2 (en) | 2003-07-31 |
AU2003210518A1 (en) | 2003-09-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004023973A3 (en) | Molecules for diagnostics and therapeutics | |
WO2002097031A3 (en) | Molecules for diagnostics and therapeutics | |
WO2000073509A3 (en) | Molecules for diagnostics and therapeutics | |
WO2004037999A3 (en) | A34 and a33-like 3 dna, proteins, antibodies thereto and methods of treatment using same | |
WO2002083876A3 (en) | Secretory molecules | |
WO2005056600A3 (en) | Monoclonal antibodies that bind or neutralize dengue virus | |
WO2005069854A3 (en) | Methods and materials relating to novel c1q domain-containing polypeptides and polynucleotides | |
WO2002046228A3 (en) | Receptor for b. anthracis toxin | |
WO2003020894A3 (en) | Insulin related transcription factor and uses thereof | |
WO2003062376A3 (en) | Molecules for diagnostics and therapeutics | |
WO2002040715A8 (en) | Molecules for disease detection and treatment | |
WO2002020756A3 (en) | Secretory molecules | |
WO2002078526A3 (en) | Cancer-testis antigens | |
WO2003062385A3 (en) | Secretory molecules | |
WO2004066933A3 (en) | Compositions and methods for treating cancer using igsf9 and liv-1 | |
WO2001062927A3 (en) | Polypeptides and corresponding polynucleotides for diagnostics and therapeutics | |
WO2001062922A3 (en) | Polypeptides and corresponding molecules for disease detection and treatment | |
WO2002020754A3 (en) | Molecules for diagnostics and therapeutics | |
WO2002055738A3 (en) | Molecules for disease detection and treatment | |
WO2001062918A3 (en) | Secretory polypeptides and corresponding polynucleotides | |
WO2002079473A3 (en) | Molecules for diagnostics and therapeutics | |
WO2001021836A3 (en) | Molecules for diagnostics and therapeutics | |
WO2008124170A3 (en) | SELECTION OF HUMAN TNFα SPECIFIC ANTIBODIES | |
WO2003008626A3 (en) | Novel human nucleic acids encoding a pantothenate kinase and methods of use | |
WO2000075298A8 (en) | Molecules for disease detection and treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |